Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors

Inclusion Criteria: * Diagnosis of high-risk solid tumors known to express at least 2 targeted antigens by either histology or historical reference: Ewing sarcoma, Wilms tumor, neuroblastoma, rhabdomyosarcoma, soft tissue sarcoma, and osteosarcoma. * HLA type and match through at least one allele with antigen-specific activity. * Following conventional therapy: refractory disease, residual detectable disease, or relapsed disease. * Age \>= 1 year and \<70 years * Patient or parent/guardian capable of providing informed consent. * No systemic corticosteroid exposure within 1 week of initiating protocol treatment. * Karnofsky/Lansky score of ≥50%. * For participant with history of total body irradiation (TBI), radiation to thorax, or treatment with cardiotoxic chemotherapy (anthracycline or equivalent): Left ventricular ejection fraction (LVEF) \>50% OR left ventricular fractional shortening (FS) \>27% (may be performed within the last 12 months, and after completion of such treatment/s) * Hemoglobin \>7.0 g/dL (level can be achieved with transfusion). * Direct bilirubin ≤2.5 mg/dL or 3x ULN (whichever is higher). * Aspartate transaminase (AST)/Alanine transaminase (ALT) ≤5 x the upper limit of normal for age. * Serum creatinine \<1.0 mg/dL or 2x the upper limit of normal for age (whichever is higher). * Pulse oximetry of \>90% on room air. * Respiratory rate: * \<30 breaths per minute for patients aged \<18 years * \<25 breaths per minute for patients aged ≥18 years * Respira…